Bladder Cancer


FDA Approves Opdivo for Treatment of Bladder Cancer (February 16, 2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a... Continue Reading

Keytruda Immunotherapy Improves Overall Survival in Bladder Cancer (November 10, 2016)

Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average age that patients are diagnosed with bladder cancer is 70 years, with 80% of these patients... Continue Reading

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor,... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy.... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to... Continue Reading

Durvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients with PD-L1 Positive Urothelial Bladder Cancer (February 19, 2016)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1... Continue Reading

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (January 21, 2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently... Continue Reading

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at... Continue Reading

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment.... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014... Continue Reading

Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)

A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1... Continue Reading

Ask the MD What Causes Bladder Cancer (February 26, 2014)

Michael O’Donnell, MD Director of Urologic Oncology, Department of Urology University of Iowa Hospitals and Clinics Bladder cancer is the fourth most common new cancer in men and the tenth in women.... Continue Reading

What You Should Know About Bladder Cancer (January 27, 2014)

Michael O’Donnell, MD Director of Urologic Oncology University of Iowa Hospitals and Clinics Bladder cancer is the fourth most common new cancer in men and the tenth in women. About 70,000 new cases... Continue Reading

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 8, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS